No profile data available.
Cytokinetics, Incorporated (CYTK) is a healthcare company in the cardiac treatment pharmaceuticals industry, based in South San Francisco, United States, with about 673 full-time employees.
It reported revenue of $88.04 million for fiscal year 2025, up 376.6% from fiscal year 2024, and net income of -$784.96 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $28.62 million, down 57.1% from a year before. Its market capitalization was $8.75 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Cytokinetics reported $88.04 million in revenue for fiscal year 2025, up 376.6% from $18.47 million in fiscal year 2024. In Q2 2026 revenue was $28.62 million.
$8.75 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (cardiac treatment pharmaceuticals) include Lexicon Pharmaceuticals, Inc. (LXRX), Lexeo Therapeutics, Inc. (LXEO), Cardiol Therapeutics Inc. (CRDL), Tenaya Therapeutics, Inc. (TNYA).